Evidence map›Paper›PMID 29954459›Full record

ArticleBMC research notes2018

Identification of cyclic hexapeptides natural products with inhibitory potency against Mycobacterium tuberculosis.

Sheo B Singh, Joshua Odingo, Mai A Bailey, Bjorn Sunde, Aaron Korkegian, Theresa O'Malley, Yulia Ovechkina, Thomas R Ioerger, James C Sacchettini, Katherine Young and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC research notes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sheo B SinghMerck & Co., Inc., Infectious Diseases, 770 Sumneytown Pike, West Point, PA, 19486, USA.
Joshua OdingoTB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue E, Suite 400, Seattle, WA, 98102, USA.
Mai A BaileyTB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue E, Suite 400, Seattle, WA, 98102, USA.
Bjorn SundeTB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue E, Suite 400, Seattle, WA, 98102, USA.
Aaron KorkegianTB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue E, Suite 400, Seattle, WA, 98102, USA.
Theresa O'MalleyTB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue E, Suite 400, Seattle, WA, 98102, USA.
Yulia OvechkinaTB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue E, Suite 400, Seattle, WA, 98102, USA.
Thomas R IoergerTexas A&M University, College Station, TX, USA.
James C SacchettiniTexas A&M University, College Station, TX, USA.
Katherine YoungMerck & Co., Inc., Infectious Diseases, 770 Sumneytown Pike, West Point, PA, 19486, USA.
David B OlsenMerck & Co., Inc., Infectious Diseases, 770 Sumneytown Pike, West Point, PA, 19486, USA.
Tanya ParishTB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue E, Suite 400, Seattle, WA, 98102, USA. tanya.parish@idri.org.ORCID http://orcid.org/0000-0001-7507-0423

Funding

Bill and Melinda Gates Foundation OPP1024038
6 · The paper itself

Abstract

objectiveOur aim was to identify natural products with anti-tubercular activity.

resultsA set of ~ 500 purified natural product compounds was screened for inhibition against the human pathogen Mycobacterium tuberculosis. A series of cyclic hexapeptides with anti-tubercular activity was identified. Five analogs from a set of sixteen closely related compounds were active, with minimum inhibitory concentrations ranging from 2.3 to 8.9 μM. Eleven structural analogs had no significant activity (MIC > 20 μM) demonstrating structure activity relationship. Sequencing of resistant mutant isolates failed to identify changes accounting for the resistance phenotype.

Indexed as

Antitubercular AgentsBiological ProductsHumansMicrobial Sensitivity TestsMycobacterium tuberculosisOligopeptidesStructure-Activity RelationshipAntitubercular AgentsBiological ProductsOligopeptidesAntibacterialAntibiotic resistanceAnti-tubercularMycobacteriaNatural product

Identifiers

PMID29954459
PMCPMC6022709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.